Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ASA 100 mg Clear all
Completed Phase 3 Interventional Results available

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

NCT01994720
View directory record Official record
Conditions
Acute Ischaemic Stroke, Transient Ischaemic Attack
Interventions
ticagrelor, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
13,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
115
States / cities
Montgomery, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 112 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

Minocycline and Aspirin in the Treatment of Bipolar Depression

NCT01429272
View directory record Official record
Conditions
Bipolar Disorder Depression
Interventions
Minocycline, Aspirin, placebo
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Wichita, Kansas • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 7, 2026, 11:47 PM EDT
Not listed Phase 2 Interventional

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

NCT02791958
View directory record Official record
Conditions
Hypertension
Interventions
Cardiovascular Fixed Dose Combination Pill AAR, Atorvastatin 40 mg, Ramipril 10 mg
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years to 74 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 7, 2026, 11:47 PM EDT
Not listed Phase 3 Interventional

ACL-R Opioid Sparing Study

NCT06561035
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Opiate Sparing, Opiate Based
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
14 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 7, 2026, 11:47 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Aspirin in Reducing Events in the Elderly

NCT01038583
View directory record Official record
Conditions
Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression
Interventions
100 mg enteric-coated aspirin, Placebo
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
65 Years and older
Enrollment
19,114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

NCT00501059
View directory record Official record
Conditions
Moderate Risk of CVD
Interventions
Aspirin (Acetylsalicylic acid, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
55 Years and older
Enrollment
12,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
73
States / cities
Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

NCT02217501
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel, Acetylsalicylic acid (ASA)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Davenport, Iowa • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

PeriOperative ISchemic Evaluation-2 Trial

NCT01082874
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Active Clonidine, Placebo Clonidine, Active ASA, Placebo ASA
Drug
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
45 Years and older
Enrollment
10,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

NCT02239120
View directory record Official record
Conditions
Stroke, Secondary Prevention
Interventions
optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 150 Years
Enrollment
5,390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
110
States / cities
Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 7, 2026, 11:47 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants

NCT07652723
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Aspirin, BAY3389934
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 7, 2026, 11:47 PM EDT
Terminated Not applicable Interventional Results available

Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors

NCT01965002
View directory record Official record
Conditions
Soft Tissue Neoplasms
Interventions
MRgHIFU, Aspirin, Enoxaparin
Device · Drug
Lead sponsor
Pejman Ghanouni
Other
Eligibility
10 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

NCT01830543
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
86
States / cities
Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

NCT00528411
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

NCT03844191
View directory record Official record
Conditions
Coronary Disease
Interventions
RUC-4 Compound
Drug
Lead sponsor
CeleCor Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

Aggrenox To Treat Acute Covid-19

NCT04410328
View directory record Official record
Conditions
Covid19
Interventions
Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
19 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 7, 2026, 11:47 PM EDT
Terminated Phase 1 Interventional

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

NCT05625347
View directory record Official record
Conditions
Obstructive Pulmonary Function, Restrictive Pulmonary Function
Interventions
single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 7, 2026, 11:47 PM EDT
Terminated Phase 3 Interventional Results available

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

NCT02313909
View directory record Official record
Conditions
Stroke
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
7,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
38
States / cities
Tucson, Arizona • Long Beach, California • Stanford, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 7, 2026, 11:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

NCT00984113
View directory record Official record
Conditions
Renal Impairment
Interventions
Elinogrel
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Not applicable Interventional Results available

Enoxaparin Versus Aspirin in Patients With Cancer and Stroke

NCT01763606
View directory record Official record
Conditions
Cancer Patients First-ever Acute Ischemic Stroke
Interventions
Enoxaparin, Aspirin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.

NCT05625334
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASA, non-enteric-coated chewable aspirin
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

NCT02834403
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
L-NMMA, Docetaxel, Amlodipine, Pegfilgrastim, Enteric-coated aspirin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

NCT01776424
View directory record Official record
Conditions
Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Sep 7, 2026, 11:47 PM EDT
Completed Phase 2 Interventional

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

NCT01259817
View directory record Official record
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions
PEGASYS, Aspirin
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 7, 2026, 11:47 PM EDT